Publications by authors named "Andreas Altemark"
Achieving balance in the treatment and monitoring of neovascular age-related macular degeneration in the real world: lessons from the Netherlands cohort of the AURA study.
Acta Ophthalmol
March 2019
Article Synopsis
- The study focused on the real-world effectiveness of antivascular endothelial growth factor agents, particularly ranibizumab, in treating diabetic macular edema (DME) over 12 months.
- Results showed a mean visual acuity improvement of 4.4 letters and a notable reduction in central retinal thickness, highlighting the treatment's impact.
- However, the outcomes in this real-world setting were lower compared to results from controlled clinical trials, suggesting potential differences in effectiveness in everyday medical practice.
Objective: AURA was an observational study that monitored visual acuity outcomes following ranibizumab use in neovascular age-related macular degeneration patients over 2 years. The aim of this analysis was to identify factors that were predictive of visual acuity outcomes in AURA.
Methods: The correlation between the baseline characteristics, the use of resources and the visual acuity outcomes in AURA was explored using principal component analysis (PCA) and partial least-squares-discriminant analysis (PLS-DA).
Background/aims: To identify predictive markers for the outcomes of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration (nAMD).
Methods: AURA was a retrospective, observational, multicentre study that monitored the 2-year outcomes following intravitreal ranibizumab treatment in patients with nAMD. Using stepwise regression analysis, we evaluated the association between visual acuity outcomes, baseline characteristics and resource utilisation in order to determine which variables are significantly linked to outcomes in AURA.